atabecestat
Small moleculeexperimental
Clinical trial activity
15 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01827982)
Timeline
Indications
Mechanism of action
- Beta-secretase 1INHIBITOR
BACE1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@]1(c2cc(NC(=O)c3ccc(C#N)cn3)ccc2F)C=CSC(N)=N1- Mol. weight
- 367.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3916243 ↗
Also known as
- jnj-54861911
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03587376 | Early Phase 1 (Phase 1) | May 30, 2018 | Johnson and Johnson |
| NCT02611518 | Phase 1 | Apr 1, 2016 | Johnson and Johnson |
| NCT02569398 | Phase 2/Phase 3 (Phase 3) | Nov 23, 2015 | Johnson and Johnson |
| NCT02406027 | Phase 2 | Jul 2, 2015 | Johnson and Johnson |
| NCT02360657 | Phase 1 | Feb 1, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT02355561 | Phase 1 | Jan 1, 2015 | Johnson and Johnson |
| NCT02260674 | Phase 2 | Nov 1, 2014 | Johnson and Johnson |
| NCT02211079 | Phase 1 | Sep 1, 2014 | Johnson and Johnson |
| NCT02197884 | Phase 1 | Jul 1, 2014 | Johnson and Johnson |
| NCT02152332 | Phase 1 | Jul 1, 2014 | Johnson and Johnson |
| NCT02180269 | Phase 1 | Jun 1, 2014 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01978548 | Phase 1 | Dec 1, 2013 | Johnson and Johnson |
| NCT02260700 | Phase 1 | Sep 1, 2013 | Johnson and Johnson |
| NCT01887535 | Phase 1 | May 1, 2013 | Johnson and Johnson |
| NCT01827982 | Phase 1 | Mar 1, 2013 | Johnson and Johnson |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 15 | 15 | 3 | 2013 |
| Janssen Pharmaceutica NV | For profit | 2 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1